Screener / SEC EDGAR /CIK 0001757073 /10-K filed Feb 12, 2026, compared with Feb 13, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Dental Equipment & Supplies

Envista Holdings Corp NVST

Compare with peers Embed
SEC comment letters, last 20 years

2 reviews of NVST's filings by SEC staff

UPLOAD and CORRESP
Reviews 2 latest letter Nov 24, 2020
Questions asked 13 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 3 UPLOAD
  2. 2. Questions in them 13 numbered comments
  3. 3. Company replies 2 CORRESP
  4. 4. Reviews closed 1 of 2 closing letter

Half the closed reviews took 15 days or less from the first letter to the closing letter.

Form 10-K for the Fiscal Year Ended December 31, 2019

2020-11-24 to 2020-12-09 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2020-12-09
Non-GAAP measuresResults discussion (MD&A)
Management's Discussion and Analysis · Non-GAAP Measures, page 51
SEC asked
With respect to your disclosures relating to Sales and Non-GAAP Measures, please address the following: • You present a discussion of your Non-GAAP Measures on page 51 and a narrative beginning on page 53 focused on your core sales growth, a non-GAAP measure. A similar presentation is included beginning on page 43 of your October 3, 2020 Form 10-Q.
Rest of the question

Please confirm that you will revise your presentation in future periodic reports to quantify and explain significant factors that affected your GAAP sales preceded by any discussion of your non-GAAP measures. • Please confirm you will quantify the effect that changes in price versus volume had on the change in sales in future filings. For example, we noted a significant decline in sales in the nine months ended October 2, 2020 for which it is unclear how much of the decline related to price versus volume and if the decrease in volume was related solely to COVID-19 or other factors. • Your presentation beginning on page 7 in Exhibit 99.1 of the Form 8-K filed October 29, 2020 appears to include a full income statement presentation of non-GAAP measures which does not appear to comply with Question 102.10 of the Non-GAAP Financial Measures Compliance and Disclosure Issues. Please confirm you will revise your presentation in future earnings releases.

NVST answered
The Company confirms that:

•In future periodic reports it will revise its presentation to quantify and explain significant factors that affected the Company’s GAAP sales to precede any discussion of the Company’s related non-GAAP measures.

•With respect to Management’s Discussion and Analysis, in future filings it will quantify the effect that changes in price versus volume had on the change in sales, including the impact of COVID-19, if any.

•With respect to future earnings releases, it will revise its presentation to exclude full income statement presentations of non-GAAP measures and
Rest of the answer

will comply with Question 102.10 of the Non-GAAP Financial Measures Compliance and Disclosure Interpretations.

Read in the reply
In its next report

First report after the company's reply of Dec 3, 2020: 10-K filed Feb 19, 2021 ↗, against the 10-K filed Feb 21, 2020 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2020-12-09

Form S-1

2019-06-14 to 2019-08-12 · 12 questions · 2 letters from the SEC, 1 from the company
No closing letter
Results discussion (MD&A)DebtLiquidity and cashRisk factors
SEC letter of Jun 14, 2019 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Draft Registration Statement on Form S-1 Submitted May 20, 2019 · Risks Related to the Separation and our Relationship with Danaher, page 5
SEC asked (1)
Revise the sixth bullet point to discuss the elimination of the conversion feature upon transfer of the Class B shares.
NVST answered

No reply letter found.

Draft Registration Statement on Form S-1 Submitted May 20, 2019 · Risks Related to the Separation and our Relationship with Danaher, page 5
SEC asked (2)
We note your disclosure in the last bullet point that you will have debt obligations following your separation from Danaher. Please revise to quantify the debt obligations.
NVST answered

No reply letter found.

Following the separation and this offering..., page 31
SEC asked (3)
Revise to disclose the percentage of outstanding shares that high-vote shareholders must keep to continue to control the outcome of matters submitted to shareholders for approval.
NVST answered

No reply letter found.

Our Class B common stock may remain as a separate class..., page 32
SEC asked (4)
Revise to discuss the elimination of the conversion feature of your Class B shares upon transfer, as discussed on page 134, and its impact on Class A shareholders. Also, revise your disclosure here and on page 134 to discuss the likelihood of mandatory conversion by shareholder approval given the high-vote status of the Class B shares. We cannot predict the impact our dual class structure..., page 38
NVST answered

No reply letter found.

Our Class B common stock may remain as a separate class..., page 32
SEC asked (5)
Revise your disclosure to discuss the potential adverse impact on liquidity of your Class A shares if such shares are ineligible for inclusion in certain indices due to your dual class structure.
NVST answered

No reply letter found.

Your percentage ownership in us may be diluted in the future, page 40
SEC asked (6)
Revise to discuss the dilutive effect to Class A shareholders of future issuances of highvote shares.
NVST answered

No reply letter found.

Nobel Biocare Systems, page 85
SEC asked (7)
Expand your discussion here of the N1 implant system to address the regulatory approval process, including what steps you have taken and what steps remain. Furthermore, balance your disclosure to state that you may not receive regulatory approval. Also, clarify how your system may be more efficient than currently used drilling protocols. Sales and Distribution, page 89
NVST answered

No reply letter found.

Nobel Biocare Systems, page 85
SEC asked (8)
Revise your disclosure to discuss the material terms of any long-term agreements you have with your significant distributor. File the agreements as exhibits or advise. If you do not have any long-term agreements with your significant distributor, revise your disclosure here and in your third risk factor on page 17 to clarify.
NVST answered

No reply letter found.

Certain Relationships and Related Person Transactions, page 126
SEC asked (9)
Please disclose the term and termination provisions of the Tax Matters Agreement and the Employee Matters Agreement mentioned on pages 130-132.
NVST answered

No reply letter found.

Certain Relationships and Related Person Transactions, page 126
SEC asked (10)
Please disclose the portion of your business affected by the Intellectual Property Matters Agreement and the DBS License Agreement mentioned on page 132.
NVST answered

No reply letter found.

Signatures, page II-4
SEC asked (1)
Please revise to ensure that the registration statement is signed by at least a majority of the board of directors.
NVST answered
The Company respectfully advises the Staff that the registration statement on Form S-1 was signed by all of the existing members of the board of directors of the Company. The

Company’s board of directors currently consists of Amir Aghdaei, William K. Daniel II and Daniel A. Raskas. The other individuals identified on page 103 of the prospectus as individuals who are expected to serve as directors immediately prior to the closing of the offering are director nominees who are expected to be appointed to the board immediately prior to the closing of the offering.
Rest of the answer

The disclosure on page 103 of the prospectus has been revised accordingly to identify those individuals who are director nominees.

Read in the reply
Exhibits
SEC asked (2)
We note your disclosure in the last sentence on page 43 regarding the scope of your exclusive forum provision. Please ensure that Article IX of your amended and restated certificate of incorporation filed as exhibit 3.1 clearly states that the provision does not apply to actions arising under the Securities Act or Exchange Act.
NVST answered
In accordance with the Staff’s comment, Article IX of the Company’s amended and restated certificate of incorporation has been revised and filed as exhibit 3.1 to Amendment No. 1.

* * *

We thank you for your prompt attention to this letter and look forward to hearing from you at your earliest convenience. Please direct any questions concerning this filing to the undersigned at (212) 735-7886 or [email protected].
Read in the reply

Letters without questions

Other letters

UPLOAD and CORRESP
3 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 9 letters filed since 2019-06-18. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/NVST/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.